Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment

Market Focus09-17

On September 17, Caris Life Sciences, Inc. rose 5.35% in regular trading, trading at $29.82 per share with turnover of $29.88 million, extending its recent strong momentum. The rally was driven by a combination of better-than-expected quarterly results and fresh institutional coverage.

On the earnings front, the company reported Q2 revenue of $263.7 million, significantly beating the consensus estimate of $238.1 million. Its Q1 results were equally impressive, with revenue surging 79% year-over-year and EPS reaching breakeven versus an expected loss. Full-year revenue guidance of $1.0 billion to $1.02 billion was reaffirmed. Most recently, UBS initiated coverage with a Neutral rating and a $28 price target, while the average analyst rating stands at Overweight with a mean target of $27.08.

On the product side, the company has continued to expand its precision oncology portfolio with the launch of a PTEN IHC assay for metastatic prostate cancer and ChromoSeq whole genome sequencing for myeloid malignancies. A previously authorized $100 million share buyback plan further reinforced market confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186996378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186996378","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment","media":"Market Focus","content":"<p><p>On September 17, Caris Life Sciences, Inc. rose 5.35% in regular trading, trading at $29.82 per share with turnover of $29.88 million, extending its recent strong momentum. The rally was driven by a combination of better-than-expected quarterly results and fresh institutional coverage.</p><p>On the earnings front, the company reported Q2 revenue of $263.7 million, significantly beating the consensus estimate of $238.1 million. Its Q1 results were equally impressive, with revenue surging 79% year-over-year and EPS reaching breakeven versus an expected loss. Full-year revenue guidance of $1.0 billion to $1.02 billion was reaffirmed. Most recently, UBS initiated coverage with a Neutral rating and a $28 price target, while the average analyst rating stands at Overweight with a mean target of $27.08.</p><p>On the product side, the company has continued to expand its precision oncology portfolio with the launch of a PTEN IHC assay for metastatic prostate cancer and ChromoSeq whole genome sequencing for myeloid malignancies. A previously authorized $100 million share buyback plan further reinforced market confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, Caris Life Sciences, Inc. rose 5.35% in regular trading, trading at $29.82 per share with turnover of $29.88 million, extending its recent strong momentum. The rally was driven by a combination of better-than-expected quarterly results and fresh institutional coverage.</p><p>On the earnings front, the company reported Q2 revenue of $263.7 million, significantly beating the consensus estimate of $238.1 million. Its Q1 results were equally impressive, with revenue surging 79% year-over-year and EPS reaching breakeven versus an expected loss. Full-year revenue guidance of $1.0 billion to $1.02 billion was reaffirmed. Most recently, UBS initiated coverage with a Neutral rating and a $28 price target, while the average analyst rating stands at Overweight with a mean target of $27.08.</p><p>On the product side, the company has continued to expand its precision oncology portfolio with the launch of a PTEN IHC assay for metastatic prostate cancer and ChromoSeq whole genome sequencing for myeloid malignancies. A previously authorized $100 million share buyback plan further reinforced market confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAI","symbol_name":"Caris Life Sciences, Inc.","start_time":0,"source_url":"","article_id":"1186996378","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186996378","pubTimestamp":1789655504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, Caris Life Sciences, Inc. rose 5.35% in regular trading, trading at $29.82 per share with turnover of $29.88 million, extending its recent strong momentum. The rally was driven by a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAI":"Caris Life Sciences, Inc."},"translate_title":"走势警报|Caris Life Sciences, Inc. 常规交易中上涨 5.35%，盈利超出预期和机构报道继续提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":1},"content_text":"On September 17, Caris Life Sciences, Inc. rose 5.35% in regular trading, trading at $29.82 per share with turnover of $29.88 million, extending its recent strong momentum. The rally was driven by a combination of better-than-expected quarterly results and fresh institutional coverage.On the earnings front, the company reported Q2 revenue of $263.7 million, significantly beating the consensus estimate of $238.1 million. Its Q1 results were equally impressive, with revenue surging 79% year-over-year and EPS reaching breakeven versus an expected loss. Full-year revenue guidance of $1.0 billion to $1.02 billion was reaffirmed. Most recently, UBS initiated coverage with a Neutral rating and a $28 price target, while the average analyst rating stands at Overweight with a mean target of $27.08.On the product side, the company has continued to expand its precision oncology portfolio with the launch of a PTEN IHC assay for metastatic prostate cancer and ChromoSeq whole genome sequencing for myeloid malignancies. A previously authorized $100 million share buyback plan further reinforced market confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186996378","isCrawlerRequest":true}